Table 2.
Score | Placebo T0 | Placebo T1 | Placebo T2 | Tx T0 | Tx T1 | Tx T2 | P site | PTx | PTime | PTx*time |
---|---|---|---|---|---|---|---|---|---|---|
Lameness | 3 (1–4) | 2.5 (2–3) | 2 (1–3) | 3 (1–4) | 3 (2–4) | 2 (1–3) | 0.92 | 0.25 | <0.001 | 0.98 |
Pain | 3 (1–3) | 1 (1–3) | 1 (1–3) | 3 (2–3) | 2 (1–2) | 1 (1–3) | <0.001 | 0.91 | <0.001 | 0.66 |
Weight-bearing | 3 (1–4) | 3 (2–3) | 2 (1–3) | 3 (1–5) | 3 (2–3) | 2.5 (1–3) | 0.28 | 0.17 | <0.001 | 0.70 |
Results reported as median (range) at week 0 (T0; initial evaluation before surgery) and at 2 and 4 weeks post-operatively (T1 and T2, respectively). P-values < 0.05 considered significant and evaluated effect of site (FL vs. RB) treatment (PTx), effect of time (PTime), and effect of treatment over time (PTx*time) by a mixed model analysis of Wilcoxon Signed rank test and Tukey's tests.